Travoprost is a PGF2a analog that was launched as an ophthalmic solution administered topically for the treatment of elevated intraocular hypertension as a result of open-angle glaucoma, a common optic neuropathy, and a leading cause of blindness. It can act as an agonist of prostaglandin F receptor.
Travoprost has sub-micromolar affinity for the DP, EP1, EP3, EP4, IP, and TP receptors.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Travoprost produces a lower incidence of ocular irritation than PGF20 isopropyl ester at a dose of 1 μg in the New Zealand albino (NZA) rabbit. Topical ocular application of Travoprost produces a marked miotic effect in cats following doses of 0.01, 0.03 and 0.1 μg. In the ocular hypertensive monkey, b.i.d. application of 0.1 and 0.3 μg of travoprost afforded peak reduction in intraocular pressure (IOP) of 22.7% and 28.6%, respectively. Topical application of travoprost was well tolerated in rabbits, cats and monkeys, causing no ocular irritation or discomfort at doses up to 1 μg.
Related Prodcuts: (+)-Cloprostenol; Cloprostenol; Misoprostol; Carboprost; Tafluprost; Dinoprostone; Dinoprost; Trometamol; Alprostadil; Iloprost; Limaprost; Bimatoprost; Latanoprost; Lubiprostone; 15-keto Travoprost; 15S-Travoprost; 5,6-trans Travoprost; Fluprostenol Travoprost acid; Travoprost intermediate